Age Limit for Mobic (Meloxicam)
Mobic (meloxicam) is approved for use in children aged 2 years and older for juvenile idiopathic arthritis (JIA), with safety and efficacy established in pediatric patients from 2 to 17 years of age. 1
Pediatric Use
The FDA-approved drug label explicitly states that "the safety and effectiveness of meloxicam in pediatric JRA patients from 2 to 17 years of age has been evaluated in three clinical trials" 1. This establishes 2 years as the lower age limit for meloxicam use in children.
Dosing Considerations by Age
For children 2 years and older:
- Dosing is weight-based at 0.125 mg/kg once daily (maximum 7.5 mg/day) 1
- Clinical trials demonstrated comparable efficacy and safety between meloxicam 0.125 mg/kg and 0.25 mg/kg doses versus naproxen in children with JIA 2
Pharmacokinetic differences exist between age groups:
- Younger children (2-6 years) show approximately 30% lower drug exposure compared to older children (7-16 years) 1
- Body weight, not age, is the primary predictor of meloxicam clearance in pediatric patients 1
- Elimination half-life is similar across pediatric age groups: 15.2 hours in 2-6 year-olds versus 13.0 hours in 7-16 year-olds 1
Important Caveats
Children under 2 years: The pharmacokinetics and safety of meloxicam have not been investigated in this population 1. Use is not recommended due to lack of data.
Alternative NSAIDs for younger children: According to recent guidelines for polyarticular JIA, if meloxicam is unavailable or contraindicated, alternative NSAIDs approved for pediatric use include ibuprofen, indomethacin, tolmetin, etodolac, ketorolac, oxaprozin, and celecoxib 3. However, naproxen remains the preferred first-choice NSAID based on its evidence-supported efficacy and safety profile in children 3.
Upper Age Limit
No upper age limit exists for meloxicam use. In geriatric patients (≥65 years), no dose adjustment is necessary, though caution is advised 1. Elderly females may experience 47% higher drug exposure compared to younger females, but the adverse event profile remains comparable 1.